|
|
|
|
Vol. 63, Issue 4, 784-790, April 2003
B by
-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors Leads
to Transcription of p53 and Cell Death in Dopaminergic Neurons
Departments of Psychiatry (G.A.d.E., D.A.D., D.M., M.D., K.D.) and Neurology (G.A.d.E., T.W., M.P.G., L.L.D.) and Center for the Study of Nervous System Injury (G.A.d.E., K.H., M.P.G., L.L.D.), Washington University School of Medicine, St. Louis, Missouri; Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina (D.H.M.); and Departamento de Biología Celular, Universidad de Valencia, Valencia, Spain (M.S., J.M.G.V.)
| |
Abstract |
|---|
|
|
|---|
We describe a new molecular mechanism of cell death by excitotoxicity
mediated through nuclear transcription factor
B (NF
B) in rat
embryonic cultures of dopaminergic neurons. Treatment of mesencephalic
cultures with
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) resulted in a number of changes that occurred selectively in
dopaminergic neurons, including persistent elevation in intracellular Ca2+ monitored with Fura-2, and a significant increase in
intramitochondrial oxidation of dihydrorhodamine 123, probably
associated with transient increase of mitochondrial permeability,
cytochrome c release, nuclear translocation of NF
B,
and transcriptional activation of the oncogene
p53. Interruption of any of these steps by
specific antagonists prevented neurite pruning and programmed cell
death. In contrast, cell death was not prevented by caspase antagonists and only partly prevented by nitric-oxide synthase inhibitors. This signal transduction pathway might be a contributing mechanism in
ongoing neuronal death in Parkinson disease.
| |
Introduction |
|---|
|
|
|---|
Parkinson
disease (PD) is among the most prevalent neurological disorders in the
elderly, and loss of mesencephalic dopaminergic neurons (DNs) is
considered the cause of the motor symptoms of the illness. The reasons
for the selective susceptibility of DNs in PD are poorly understood.
Experimental and pathological data implicate a susceptibility of DNs to
oxidative stress triggered by endogenous or exogenous toxins. Oxidative
stress has been demonstrated in brain and in cell models of PD
(Cassarino et al., 2000
). In late stages of PD, the substantia nigra
exhibits increased lipid peroxidation, superoxide dismutase activity,
and iron content, and glutathione levels are decreased, very likely
favoring oxidative stress (Hirsch et al., 1991
; Jellinger et al.,
1993
). DNs may display an increased susceptibility to premature death
because of poor calcium (Ca2+) homeostasis (de
Erausquin et al., 1994
), insufficient Ca2+
buffering by Ca2+ binding proteins (German et
al., 1992
; Damier et al., 1999
), increased requirement for trophic
factor support, and abnormal proteosome degradation (McNaught and
Jenner, 2001
). In late PD stages, there is evidence of apoptosis
(Mochizuki et al., 1996
; Anglade et al., 1997
), but other forms of cell
death may also play a role (Jellinger, 2001
). Direct damage to
macromolecules by lipid peroxidation (Jenner, 1998
) or release of tumor
necrosis factor
(TNF
) by microglia (Hunot et al., 1997
; Hartmann
et al., 2002
) has been suggested. Transcription factor NF
B nuclear translocation
which may be triggered by TNF
is found during
post-mortem examination to be increased in brains of persons with PD
(Hunot et al., 1997
). The relevance of this mechanism in PD was
questioned (Jellinger, 2001
), in part because NF
B is neuroprotective
in other neuronal phenotypes (Mattson et al., 2000
).
To elucidate the mechanism of susceptibility of DNs, we studied
cultures of mesencephalon, which allow in vitro comparisons of
individual DNs with neurons expressing other phenotypes. In this
system, DNs show unique physiologic properties
compared with nondopaminergic neurons
and, like DNs in vivo (Bywood and Johnson, 2000
), are selectively susceptible to GluRAMPA
receptor agonists (de Erausquin et al., 1994
; Isaacs et al., 1996
). DN
susceptibility to GluRAMPA agonist toxicity is
phenotype-specific, because other neuronal phenotypes in vitro display
trophic responses or physiologic effects, but not toxicity (de
Erausquin et al., 1994
; Isaacs et al., 1996
). After treatment with
(S)-
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA), DNs selectively display
[Ca2+]i accumulation,
either because DNs lack adequate
[Ca2+]i buffering
capacity (Isaacs et al., 1996
), because they have larger functionally
available [Ca2+]i stores
(de Erausquin et al., 1994
), or both. We tested the hypothesis that
AMPA-induced injury to DNs is mediated through activation of the
reactive oxygen species (ROS)-sensitive transcription factor NF
B and
the oncogene p53; we postulate that this signaling pathway
could account for the increased NF
B translocation observed post-mortem in PD.
| |
Materials and Methods |
|---|
|
|
|---|
Experimental Procedures and Immunohistochemistry
Cultures.
Cultures were prepared as described previously (de
Erausquin et al., 1992
). Briefly, ventral mesencephali from day 15 rat embryos (Sprague-Dawley timed mothers; Charles River Laboratories, Wilmington, MA) were mechanically dissociated and plated at a density
of 30 to 50,000 cells/cm2 on dishes or multiwell
plates coated with 15 mg/ml poly(D-lysine) (Mr 53,000; Sigma, St. Louis, MO) and 10 mg/ml laminin (Sigma). The culture medium contained Dulbecco's
modified Eagle's medium/Ham's F12 medium (50%/50%)
(Invitrogen, Carlsbad CA), 25 mM glucose, 2 mM glutamine, 10%
horse serum (Hyclone, Logan, UT), bFGF (10 ng in 500 ml; Sigma), and
insulin-transferrin-sodium selenite media supplement (Sigma). Cells
were cultured 9 days at 37°C in an atmosphere of 95% air/5%
CO2 saturated with H2O.
AMPA Toxicity.
Culture medium was exchanged with conditioned
medium containing 10, 30, or 100 µM AMPA alone or in combination with
drugs (Isaacs et al., 1996
). Cells were then returned to the incubator for the length of the experiment (24 h for viability). Drugs were dissolved in HEPES-buffered saline solution (116 mM NaCl, 5.4 mM
KCl, 0.8 mM MgSO4, 1.8 mM
NaH2PO4, 12 mM HEPES, 25 mM
NaHCO3, and 5.5 mM D-glucose, pH
7.4).
Immunohistochemistry.
Cultures were fixed in
phosphate-buffered saline containing 4% paraformaldehyde and 0.5%
glutaraldehyde for 30 min at room temperature; permeabilized in 0.25%
Triton X-100 for 10 min; blocked in 10% goat serum; and incubated in
primary antibody, followed by conjugated secondary antibody (Alexa-488
or Alexa-568; Molecular Probes, Eugene, OR). Monoclonal or polyclonal
antibodies were from commercial sources: tyrosine hydroxylase (TH;
Pelfreeze, Rogers, AK; or Chemicon, Temecula, CA), MAP2 (Roche
Molecular Biochemicals, Indianapolis IN), synapsin-1 (Chemicon),
I
B
(Abcam, Cambridge, UK), NF
Bp65 (Santa Cruz Biotechnologies,
Santa Cruz, CA), cytochrome c (BD Biosciences PharMingen,
San Diego, CA), phosphoprotein p53 (phos-p53; Zymed, South San
Francisco, CA).
Neuronal Survival. Cultures immunostained with microtubule associated protein 2 (MAP2) and TH were counted. The number of fields required to count 1000 cells on control wells (typically 52 fields at 200×) was matched in experimental wells. Values represent averages of at least three experiments.
Neurite Morphology. Digital images of DNs were captured with a cooled charge-coupled device camera (Nikon Diaphot, Nikon Apo 20× dry objective; Nikon, Tokyo, Japan), and analyzed (MetaMorph; Universal Imaging, WestChester, PA). Cell process number, length, and branch frequency were counted; lengths were measured in pixels, transformed to micrometers using standard rulers, and averaged for each cell.
Electron Microscopy. Cultures were fixed, stained with immunoperoxidase-diaminobenzidine, dehydrated, embedded in an epon/araldite mix, and cut for light (1.0 µm) or electron microscopy (EM) (80 nm). For EM (Philips EM300 TEM), sections were mounted on copper grids and stained with uranyl acetate and lead citrate. DNs were identifiable by the presence of the chromogen.
Identification of DNs.
DNs were distinguished by uptake of
5,7-dihydroxitryptamine (5,7-DHT) by briefly viewing cultures under
fluorescence (excitation, 360 nm; emission, 420 nm; Silva et al., 1988
;
de Erausquin et al., 1992
); phase contrast was used to allow
relocation. Rapid bleaching of 5,7-DHT prevented interference with
further imaging.
DHR123 Fluorescence.
Cultures incubated with
dihydrorhodamine 123 (DHR123) were imaged using a laser scanning
confocal microscope (Noran Odyssey equiped with an argon-ion laser;
excitation, 488 nm; emission, 515 nm) coupled to an inverted microscope
(Nikon Diaphot; 60× oil immersion objective Nikon Plan Apo) (Dugan et
al., 1995
). Frame-averaged images were analyzed using regions of
interest (MetaMorph). All drugs were added in a small aliquot of buffer (50 µl).
NF
B Activation
Nuclear Extracts. Experiments were terminated with iced lysis buffer [10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 10 mM HEPES, pH 7.9, plus 2 mg/ml pepstatin A, 2 mg/ml leupeptin, and 2 mg/ml L-leucinethiol]. Samples were homogenized, incubated on Nonidet P-40, and centrifuged. Pellets were resuspended in extraction buffer (420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 20 mM HEPES, pH 7.9, plus 2 mg/ml pepstatin A, 2 mg/ml leupeptin, and 2 mg/ml L-leucinethiol) and centrifuged for 15 min at 12,500 rpm (4°C). The supernatant containing the nuclear extracts was saved, and protein concentration determined (Invitrogen).
Electrophoretic Mobility Shift Assay. EMSAs were performed using a commercially available kit (Boehringer Ingelheim, Petersburg, VA). Aliquots incubated 15 min with 1 × 105 cpm of 32P-end-labeled, double-stranded oligonucleotide (5'-TCAGAGGGGACTTTCCGAGAGG-3') were run on 6% polyacrylamide gels for 105 min with 150 V (reaction buffer, 500 mM NaCl, 5 mM EDTA, 5 mM DTT, 50 mM Tris, pH 7.5, 20% glycerol, 0.4 mg/ml salmon sperm DNA). Specificity was determined by adding a 100-fold excess of unlabeled competitor DNA to the reaction. For gel supershift analysis, nuclear proteins were incubated with antibodies against p65 protein, and gel-shift analysis was performed after adding labeled oligonucleotide.
ELISA. Aliquots were transferred to 96-well plates containing high-density immobilized oligonucleotide (5'-GGGACTTTCC-3') (Trans-AM's ELISA; Active Motif, Carlsbad, CA). Anti-IgG HRP-conjugate and developing solution were added and read by spectrophotometry.
Western Blot. Cultures were lysed, and run on standard polyacrylamide gels, transferred to a nitrocellulose membrane, incubated in primary IgG antibody (1:1000), washed, incubated in alkaline phosphatase-linked secondary IgG antibody (1:2000), and imaged by chemiluminescence.
Reverse Transcriptase-PCR. Total RNA was prepared using TRIzol reagent (Invitrogen) and enriched for mRNA by an oligo(dT) spin-column kit (Oligotex; QIAGEN, Valencia, CA). mRNA was spectrophotometrically quantified and 40 ng of mRNA per reaction was used to synthesize first-strand cDNA (SuperScript RT-PCR System; Invitrogen). Semiquantitative PCR reaction aliquots were run on agarose and stained with ethidium bromide. PCR was performed for 28 and 30 cycles (1 min at 94°C, 1 min at 55°C, and 1 min at 72°C). Thirty cycles saturated the reaction. Duplicates of 28 cycle reactions were consistent with each other and were used for the results shown here. Primer sequences were: cyclophilin 5'-ATGGTCAACCCCACCGTGTT, cyclophilin 3'-CGTGTGAAGTCACCACCCT, p53left-TGAGCATCGAGCTCCCTCTG, and p53right- CACAGGCCTCAGCTGGGATAGCACCTC.
Drugs.
AMPA and
N-methyl-D-aspartic acid were from
Tocris Cookson Inc. (Ballwin, MO). Dizocilpine maleate,
1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX), 1-napthyl-acetyl spermine trihydrochloride (NAS),
N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone,
cyclosporin A (CSA),
1-[bis(p-chlorophenyl)methyl]-3[2,4-dichloro-
-(2,4-dichlorobenzyloxy) phenethyl]-imidazolium chloride,
2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridinecarboxylic acid dimethyl
ester, and sodium
1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NO) were from Sigma-RBI (Natick, MA). 5,7-DHT, DTT, PMSF, and
pyrrolidine dithiocarbamate (PDTC) were from Sigma-Aldrich (St. Louis,
MO). DHR123 was from Molecular Probes (Eugene, OR). Boc-aspartyl-(OMe)-fluoromethyl ketone was from Enzyme Systems Products
(Livermore, CA). Tacrolimus was from Fujisawa USA (Deerfield, IL). The HPNF
B oligonucleotide sequence
(5'-AGTTGAGGGGACTTTCCCAGGC-3') and C-NF
B oligonucleotide sequence
(5'-CTAATCTCCTCTAATCTCCCT-3') were from the Nucleic Acid Chemistry
Laboratory, Biotechnology Center, Washington University, (Saint Louis, MO).
| |
Results |
|---|
|
|
|---|
Morphological Characteristics of DNs Undergoing AMPA Toxicity.
Treatment with AMPA for 24 h caused concentration-dependent death
of DNs (EC50
30 µM), without significant
change in MAP2-stained/TH-negative neurons (Fig.
1a).
N-Methyl-D-aspartic acid (100-300
µM) failed to affect survival, and 3 µM dizocilpine failed to
protect against AMPA toxicity (not shown). Surviving DNs showed neurite
pruning, even after 10 µM AMPA (control, 1265 ± 109 µm; treated, 773 ± 81 µm). This AMPA concentration
failed to elicit significant cell loss (Fig. 1, a and b). AMPA-induced
pruning (shortening of neurites with loss of dendritic branching) (Fig.
1, c and d), was associated with loss of characteristic punctate
synapsin staining along the neurites of DNs (Fig. 1, e and f).
Ultrastructural analysis of DNs after 30 µM AMPA administration
revealed nuclear invagination and irregular aggregation of chromatin
consistent with excitotoxicity (Fig. 1, g-h) (Ishimaru et al.,
1999
).
|
AMPA Toxicity Requires Ca2+ Entry through
Voltage-Dependent Channels.
We reported previously that L-type
Ca2+ channel (LTCC) blockers prevent AMPA-induced
[Ca2+]i elevations in the
perikarya (but not dendrites) of DNs (de Erausquin et al., 1992
). The
LTCC blocker nimodipine (10 µM) reduced DN death (Fig.
2f) but only partially prevented pruning
(in percentage of control length, nimodipine alone, 103.8 ± 10.6;
+10 µM AMPA, 58.9 ± 9.0; +30 µM AMPA, 64.5 ± 7.5; +100
µM AMPA, 50.4 ± 6.2). Over 24 h, a small level of
activation of Ca2+-permeable
GluRAMPA could lead to DNs death. We compared the
effects of two GluRAMPA antagonists, the
nonselective NBQX (10 µM) and Joro spider toxin analog NAS (30 µM),
which selectively blocks Ca2+-permeable
receptors. NBQX reduced AMPA toxicity against DNs, whereas NAS was
ineffective (Fig. 2a).
|
Time of Commitment to Die and Mitochodrial Permeability during AMPA
Toxicity.
Annexin V is a probe for translocation of PS to the
outer leaflet of the cell membrane
an event that correlates with
commitment to die (Vermes et al., 1995
). We assessed PS translocation
in DNs using Alexa 568-conjugated Annexin V (Fig. 2b) and TH
immunostaining (Fig. 2,c). AMPA (30-100 µM) progressively increased
annexin V binding in DNs between 3 and 16 h, before cell death was
detected by propidium iodide staining (Fig. 2g). This staining was
seldom observed in non-DNs (data not shown).
|
|
AMPA Toxicity Is Mediated by Transcriptional Activation of
NF
B.
Caspases mediate many forms of Cyt-c triggered cell death
(Ravagnan et al., 2002
). Two nonselective caspase inhibitors,
N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone and
Boc-aspartyl-(OMe)-fluoromethyl ketone, failed to prevent AMPA toxicity
to DNs (Table 1). Immunostaining against activated caspase 3 was not
detectable in DNs after AMPA treatment (not shown). Cell death
triggered by oxidative stress in DNs is mediated by NF
B (Hunot et
al., 1997
). EMSA of NF
B DNA-binding proteins in nuclear extracts
from cells exposed for 2 h to 30 µM AMPA revealed a band that
shifted with anti-NF
Bp65 antibody and was eliminated by excess
unlabeled oligonucleotide but not by a random sequence oligonucleotide,
C-NF
B (Fig. 4a). This band was absent
in control extracts. When NF
B nuclear translocation was assessed by
ELISA, 30 µM AMPA treatment for 2 h significantly increased the
specific signal; this increase was prevented by the decoy
oligonucleotide HPNF
B but not by C-NF
B (Fig. 4b). NF
B is
sequestered in the cytosol by the inhibitory protein, I
B;
dissociation of I
B from NF
B is followed by degradation of I
B
and nuclear translocation of NF
B (Thanos and Maniatis, 1995
). I
B
was markedly decreased in cell extracts after 30 µM AMPA for 1 h, with some recovery after 3 h (Fig. 4, c and d). Preventing
NF
B activation with PDTC (Chung et al., 2000
), dexamethasone, or
HPNF
B, blocked AMPA toxicity (Fig. 4,e-g). C-NF
B had a marginally
protective effect on cell survival, but did not prevent NF
B
translocation. Its protective effect may be caused by mild nonspecific
protein synthesis inhibition. We controlled for the antioxidant effect
of PDTC with the spin trap reagents idebenone and PBN, as well as with
the vitamin E analog trolox, all of which failed to protect DNs (Table
1). PDTC may protect neurons through inhibition of NO synthase
(Hantraye et al., 1996
), but in vitro NO release by itself may increase DNs viability (Mohanakumar et al., 1998
). We tested the effect of the
NOS inhibitors N-nitro-arginine and
N,N-dimethyl-arginine and the NO donor DEA/NO on
AMPA toxicity. NOS inhibitors marginally increased DNs survival, and
DEA/NO increased AMPA toxicity (Table 1).
|
AMPA Toxicity Is Mediated by Activation of p53.
RT-PCR
products for p53, assessed by a semiquantitative assay normalized to
the amount of cyclophilin, were elevated in each of four experiments
after 30 µM AMPA treatment for 3 h. HPNF
B decreased the
amount of p53 mRNA in control wells and prevented the increase induced
by AMPA (Fig. 5, a and b). Treatment with 30 µM AMPA for 1 to 3 h increased phos-p53 protein in Western blots (Fig. 5, c and d), and immunohistochemistry revealed that this
increase was restricted to DNs (Fig. 5, e and h); phos-p53 expression
in DNs trends down after 3 h (Fig. 5i). The p53 inhibitor pifithrin-
, which reversibly blocks p53-dependent transcriptional activation and apoptosis (Komarov et al., 1999
), protected DNs after 30 µM AMPA treatment for 24 h (Fig. 5j).
|
| |
Discussion |
|---|
|
|
|---|
Excitotoxicity has long been implicated in the pathophysiology of
PD (Dunnett and Bjorklund, 1999
) but no direct links between experimental and pathological data are available. For instance, hyperactivity of the glutamatergic subthalamic nucleus has been implicated in the generation of symptoms and in the progression of PD
through excitotoxicity (Rodríguez et al., 1998
). The data presented here suggest that the increase in NF
B nuclear
translocation observed post-mortem in brains of PD patients may be
caused by excitotoxicity.
AMPA toxicity to DNs caused cytosolic vacuolation, mitochondrial
swelling, nuclear invagination, irregular chromatin clumping, and a
loss of synaptic contacts. These changes are consistent with
excitotoxicity but not with neuronal apoptosis (Ishimaru et al., 1999
).
Abnormal signaling seems also restricted to DNs, but we cannot
categorically exclude indirect effects of the treatment on other
neuronal phenotypes in the cultures. GluRAMPA
stimulation results in a similar
[Ca2+]i increase in all
neuronal phenotypes in our cultures, but only DNs fail to restore
baseline [Ca2+]i after
AMPA removal (de Erausquin et al., 1994
). LTCC antagonists prevent
[Ca2+]i influx to DNs
during GluRAMPA stimulation, and blocking
Ca2+ release from intracellular stores allows the
return of [Ca2+]i to
baseline levels (de Erausquin et al., 1994
). Now we show that LTCC
opening is necessary for AMPA toxicity (Fig. 2f) However, LTCC
antagonists had little effect on neurite pruning (data not shown), as
expected because of the relative enrichment of N-type channels in neurites of DNs (de Erausquin et al., 1992
). Our results also exclude the possibility that low levels of expression of Ca2+-permeable GluRAMPA
contribute significantly to toxicity, because the specific antagonist
of Ca2+-permeant GluRAMPA,
NAS, lacked protective effect.
The selectivity of AMPA toxicity may be because of a greater DNs
susceptibility to oxidative stress. In fact, AMPA increased ROS in DNs
but not in other neuronal phenotypes (Fig. 3, a and b). This increase
in ROS was prevented by NBQX. Cell death can be triggered by
Ca2+ overload leading to oxidative stress and
mitochondrial release of Cyt-c (Ravagnan et al., 2002
). We found
evidence of mitochondrial swelling and Cyt-c release soon after
exposure of DNs to toxic concentrations of AMPA. Consistent with these
findings, the mPT antagonists CSA and bongkrekic acid blocked AMPA
toxicity (Fig. 3c). The protective effect of CSA was significantly
reduced if treatment began 1 h after onset of AMPA treatment,
suggesting that mitochondrial changes occur at the time of commitment
to die. This is in agreement with the time of commitment to die
assessed by translocation of PS (Fig. 2g). CSA may protect neurons by
preventing opening of mPT (Khaspekov et al., 1999
; Matsumoto et al.,
1999
), but also by inhibiting calcineurin (Ankarcrona et al., 1996
;
Ruiz et al., 2000
). Our results indicate that in DNs, AMPA toxicity does not require calmodulin-calcineurin activation, because
calmidazolium and tacrolimus failed to afford protection (Table 1).
In DNs, Cyt-c release did not result in caspase 3 activation (Table 1).
This result prompts questions concerning the effector mechanism
of cell death. Our data indicate that NF
B signaling plays a central
role in AMPA toxicity to DNs. Two lines of evidence support this view.
First, AMPA increases NF
B translocation and decreases expression of
I
B, both at the time of commitment to die. Second, AMPA toxicity is
prevented by three NF
B antagonists with different molecular
mechanisms of action. PDTC has been shown to prevent or potentiate
apoptosis, depending on cell type and culture conditions (Erl et al.,
2000
). We found that low concentrations of PDTC prevent AMPA toxicity
(Fig. 4e). PDTC also has antioxidant properties, is a copper chelator,
and inhibits NOS (Chen et al., 2000
; Chung et al., 2000
), but other
antioxidants failed to protect DNs, and NOS inhibitors had limited
effect, suggesting that PDTC protects DNs by NF
B inhibition. Even
though NO release did not affect DNs viability by itself, it
significantly potentiated the toxicity of AMPA, suggesting that ADP
ribosylation may increase the susceptibility of DNs. Indeed, the ADP
ribosylation antagonist benzamide resulted in a degree of protection
similar to that of NOS inhibitors (data not shown).
Increased NF
B nuclear translocation in PD brains post-mortem
has been interpreted as evidence of activation of the TNF
pathway (Hunot et al., 1997
). Our data suggest that sustained
GluRAMPA activation could induce the same result.
This finding is potentially very important, if confirmed in vivo,
because excitotoxicity may be sustained chronically in PD by
subthalamic nucleus hyperactivity. Neuronal NF
B is activated by
GluRAMPA stimulation (Kaltschmidt et al., 1995
),
causing cell death in some
including mesencephalic
neuronal phenotypes (Hunot et al., 1997
; Schneider et al., 1999
; Cassarino et
al., 2000
) but protecting others against apoptosis (Mattson et al.,
2000
). In neurons, NF
B transcriptional activation causes cell death
mediated through p53 (Ryan et al., 2000
). Our data suggest that in DNs,
transcriptional activation of NFkB causes transcription of p53 mRNA,
because HPNF
B prevented the increase in p53 mRNA induced by AMPA
(Fig. 5). Also, increased phos-p53 expression was restricted to DNs
(Fig. 5, c, g, and h) and was necessary for toxicity, because the p53
inhibitor pifithrin-
completely prevented DN death. The mechanism of
action of pifithrin-
has not been completely elucidated, but it
seems to act downstream of p53 and may modulate nuclear import or
export of p53 or decrease the stability of nuclear p53 (Komarov et al.,
1999
).
In summary, we have shown that embryonic DNs are selectively
susceptible to overactivation of GluRAMPA,
resulting in neuronal death mediated through transcriptional activation
of NF
B. AMPA toxicity, if our findings are confirmed in vivo, may be
a good candidate target for neuroprotection of DNs in patients with PD.
| |
Acknowledgments |
|---|
We thank J. Xu and C. Hsu for the sequence and samples of
HPNK
B and E. Costa, J. Olney, E. Johnson, and S. B. Tekkok for their helpful suggestions.
| |
Footnotes |
|---|
Received October 22, 2002; Accepted December 20, 2002
This work was partially supported by National Institutes of Health grants (to M.P.G. and L.L.D.) and by a Joint Junior Faculty Award of the United Parkinson Foundation and the Parkinson Disease Foundation (to G.A.d.E.).
Address correspondence to: Gabriel A. de Erausquin, MD, PhD, Departments of Psychiatry and Neurology, CSNSI, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8134, St. Louis, MO 63110. E-mail: erausquing{at}neuro.wustl.edu
| |
Abbreviations |
|---|
PD, Parkinson disease;
DN, dopaminergic neuron;
TNF, tumor necrosis factor;
NF
B, nuclear transcription factor
B;
GluR, glutamate receptor;
AMPA,
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid;
ROS, reactive
oxygen species;
TH, tyrosine hydroxylase;
phos-p53, phosphoprotein p53;
MAP2, microtubule associated protein 2;
EM, electron microscopy;
5,7-DHT, 5,7-dihydroxitryptamine;
DHR123, dihydrorhodamine 123;
DTT, dithiothreitol;
PMSF, phenylmethylsulfonyl fluoride;
EMSA, electrophoretic mobility shift assay;
ELISA, enzyme-linked
immunosorbent assay;
PCR, polymerase chain reaction;
NBQX, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide;
NAS, 1-napthyl-acetyl spermine trihydrochloride;
CSA, cyclosporin A;
DEA/NO, sodium
1-(N,N-diethylamino)diazen-1-ium-1,2-diolate;
PDTC, pyrrolidine dithiocarbamate;
LTCC, L-type Ca2+
channel;
Cyt-c, cytochrome c;
mPT, mitochondrial
permeability transition;
NO, nitric oxide NOS, nitric-oxide
synthase.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. P. Fried, E. C. Hadley, J. D. Walston, A. B. Newman, J. M. Guralnik, S. Studenski, T. B. Harris, W. B. Ershler, and L. Ferrucci From Bedside to Bench: Research Agenda for Frailty Sci. Aging Knowl. Environ., August 3, 2005; 2005(31): pe24 - pe24. [Abstract] [Full Text] |
||||
![]() |
I. Potrovita, W. Zhang, L. Burkly, K. Hahm, J. Lincecum, M. Z. Wang, M. H. Maurer, M. Rossner, A. Schneider, and M. Schwaninger Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration J. Neurosci., September 22, 2004; 24(38): 8237 - 8244. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fujioka, C. Schmidt, G. M. Sclabas, Z. Li, H. Pelicano, B. Peng, A. Yao, J. Niu, W. Zhang, D. B. Evans, et al. Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-{kappa}B J. Biol. Chem., June 25, 2004; 279(26): 27549 - 27559. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||